Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Preclinical and early clinical data suggest this triple mechanism may reduce appetite and support metabolic function, though direct head-to-head comparisons with approved agents in humans are not yet available, and claims of superior potency remain unproven at this stage
This may be because the Food and Drug Administration (FDA) does not regulate dietary supplements and ingredients in transdermal weight loss patches have only been studied for their effectiveness taken orally
Pfizer's obesity franchise is broader than its triple-agonist position (the company also has oral GLP-1 candidates in development), but its specific seat at the high-efficacy triple-agonist table is narrower than its global commercial scale would imply
Clinical data shows Retatrutide preserves lean mass remarkably well during weight loss phases, with participants retaining approximately 75-85% of lost weight from fat rather than muscle
